GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Baseline Productions BSSP · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 4 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Baseline Productions

Its shares trade under the ticker BSSP. It has been listed since 28 September 2011.

Bassline Productions, Inc. develops mobile based hardware and software based products. The company is headquartered in Scottsdale, Arizona. The company went IPO on 2011-09-28. The firm is focused on commercialization of its proteins for the treatment of cancer and various infectious diseases. Its Irreversible Pepsin Fraction (IPF) is a therapeutic platform technology that can be used to facilitate a range of applications. IPF turns on the immune system to fight autoimmune diseases. IPF binds to thymus (T)-cells and turns on T helper cell type 1 (Th1) immune system responses that kill infected cells. The firm's lead compound is a suspension of IPF, which is indicated for the treatment of autoimmune diseases, such as cancer, cirrhosis and Hepatitis C. The Company's product, IMMUNE-THERAPEUTIC PROTEIN (ITP), is a therapeutic protein isolated from porsine pepsin, which is irreversible, modified, and fractionate to the sequence IPF.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
28 Sept 2011

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Baseline Productions Inc develops mobile based hardware and software based products for its users.
  • The Irreversible Pepsin Fraction technology turns on the immune system to fight autoimmune diseases effectively.
  • The lead compound IMMUNE-THERAPEUTIC PROTEIN is indicated for the treatment of cancer and Hepatitis C.

Weaknesses

  • The company is headquartered in Scottsdale, Arizona, which limits its immediate local market presence.
  • The firm went IPO on 28 September 2011, indicating a relatively long public trading history.
  • The business description mentions Bassline Productions, Inc., creating potential confusion with the Baseline Productions Inc name.

Opportunities

  • The IPF platform technology can be used to facilitate a range of applications in biotechnology.
  • The company is focused on commercialization of its proteins for the treatment of various infectious diseases.
  • The therapeutic protein ITP is isolated from porsine pepsin, offering a unique source for production.

Threats

  • The firm's lead compound is indicated for the treatment of cirrhosis, a serious liver condition.
  • The technology binds to thymus T-cells, which may present complex biological challenges for clinical trials.
  • The company operates in the Health Care sector, which faces strict regulatory scrutiny and compliance costs.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.